In pre-REP, TILs resident in tumour fragments receive—in addition to IL-2—signals through the T cell receptor (TCR) and possibly through co-stimulatory CD28 from adjacent tumour-resident antigen-presenting cells11. The gene discussed is CD28; the disease is neoplasm.